KalVista Pharmaceuticals Shares New Data on Hereditary Angioedema (HAE) at 2023 US HAEA National Summit

CAMBRIDGE, Mass. & SALISBURY, England, July 24, 2023 (VSNewsNetwork.com) - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical-stage pharmaceutical company specializing in the development and commercialization of oral, small molecule protease inhibitors, announced the presentation of new data concerning the experience of hereditary angioedema (HAE) attacks and patient preferences at the 2023 US Hereditary Angioedema Association (HAEA) National Summit in Orlando, Florida.

The company presented several studies, shedding light on the experiences and preferences of patients dealing with HAE. The studies provided insight into early HAE attack recognition, the significance of early on-demand treatment in the HAE attack journey, and patient preferences for on-demand treatment.

KalVista's CEO, Andrew Crockett, highlighted the significance of the data presented at the summit. He pointed out that it emphasizes the continuing need for effective treatments, both for those relying exclusively on on-demand therapies and those using long-term prophylaxis. The research also suggested that individuals with HAE are often well-versed in recognizing the onset of their HAE attacks and understand the importance of early treatment.

However, the study found that treatment is often delayed or avoided due to challenges related to injection or infusion therapies. Such issues impact not just those who rely solely on on-demand medications, but also patients on prophylaxis, many of whom still experience breakthrough attacks.

Crockett concluded by affirming that KalVista's oral on-demand medication, sebetralstat, aims to address these treatment gaps, facilitating more informed conversations between physicians and patients about newer options that could potentially improve the quality of life for people with HAE.

Learn more about KalVista at www.KalVista.com

Source: KalVista Pharmaceuticals via Business Wire